Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. ICIs Are Effective in the Treatment of Older Adults With mRCC
  2. Cytoreductive Nephrectomy in the Era of Targeted and Immunotherapy for Metastatic Renal Cell Carcinoma
  3. Nivolumab Plus Cabozantinib Improves Outcomes in Advanced RCC
  4. Real-World Symptoms, Disease Burden, Resource Use and Quality of Life in US Patients With Advanced RCC
  5. Preoperative Anaemia and Thrombocytosis Predict Adverse Prognosis in Non‐Metastatic RCC With Tumour Thrombus
  6. Sunitinib Treatment Promotes Metastasis of Drug-Resistant RCC Via TFE3 Signaling Pathway
  7. Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCC
  8. Peri-Operative Morbidity and Mortality Among Patients Undergoing Cytoreductive Nephrectomy
  9. Sunitinib vs Cabozantinib, Crizotinib, or Savolitinib for Metastatic Papillary RCC
  10. Sunitinib With Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary RCC

Elsewhere

Recently Updated